Yanke Chen

Dr. Yanke Chen


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2014 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
YCYanke Chen
Yanke Chen
ZZZhengfeng Zhang
Zhengfeng Zhang
XTXinqi Tang
Xinqi Tang
JLJianping Li
Jianping Li
CGClemens Glaubitz
Clemens Glaubitz
JYJun Yang
Jun Yang

18 July 2023 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
XJXintao Jing
Xintao Jing
CHCong Han
Cong Han
QLQian Li
Qian Li
FLFang Li
Fang Li
JZJinyuan Zhang
Jinyuan Zhang
CHchen huang
chen huang


15 April 2021 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
YCYanke Chen
Yanke Chen
JLJing Luan
Jing Luan
TJTing Jiang
Ting Jiang
DCDonghui Cai
Donghui Cai
CSChao Sun
Chao Sun
XGXingchun Gou
Xingchun Gou
PurposeBone destruction and pain caused by cancer is one of the most devastating complications of cancer patients with bone metastases, and it seriously affects the quality of patients’ life. Extracellular matrix metalloproteinase inducer (EMMPRIN) is a cell adhesion molecule with increased expression in a variety of tumors. This study focused to clarify the specific function of EMMPRIN in bone metastasis of breast cancer.Materials and Methods Adenovirus with shRNA-EMMPRIN was transfected into MRMT-1 rat breast carcinoma cells, and the MRMT-1 cells with different expression levels of EMMPRIN were implanted into the bone marrow cavity of rat tibia. Next, the effect of down-regulation of EMMPRIN was evaluated as follows: bone damage was detected by X-ray radiological and tartrate-resistant acid phosphatase staining; the tumor burden was evaluated by hematoxylin and eosin staining; the test of pain-related behaviors was assessed used the bilateral paw withdrawal mechanical threshold; and the levels of secretory factors in tumor conditioned medium were determined by using enzyme-linked immunosorbent assay.ResultsWe found that down-regulation of EMMPRIN in tumor cells can simultaneously reduce tumor burden, relieve cancer-induced bone destruction and pain. ConclusionMaterials and Methods EMMPRIN is expected to be a therapeutic target for relieving bone metastasis of breast cancer and alleviating cancerinduced bone destruction and pain. The method of targeting EMMPRIN may be a promising strategy for the treatment of cancer in the future.

17 July 2023 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
TJTing Jiang
Ting Jiang
JCJinfeng Chen
Jinfeng Chen
ZWZhenzhen Wang
Zhenzhen Wang
XWXiaofei Wang
Xiaofei Wang
JMJun Ma
Jun Ma
YCYanke Chen
Yanke Chen

26 November 2025 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
LZLinmei Zhang
Linmei Zhang
HZHaozhe Zhang
Haozhe Zhang
CWChenxi Wang
Chenxi Wang
AJAoxin Jiang
Aoxin Jiang
FZFei Zhao
Fei Zhao
YCYanke Chen
Yanke Chen
The transcription factor ZBTB7B has been identified as a potential tumor suppressor through a CRISPR–Cas9-based functional screen of tumor-associated genes, as overexpression of ZBTB7B could significantly suppress tumor growth in the models of breast cancer brain metastasis, which prompted our further exploration of its inhibitory role in glioma. To elucidate the underlying mechanisms of this suppressive effect, lentiviral-mediated ZBTB7B overexpression was established in U118 and GL261 glioma cell lines, and systematic evaluation of tumorigenic capacity was performed through in vitro and xenograft assays. The results showed that ZBTB7B transcriptionally activated GPR17 expression, which suppressed protein kinase A phosphorylation, amplified mitochondrial reactive oxygen species generation, and triggered Caspase3-dependent apoptosis. Meanwhile, ZBTB7B upregulated CXCL10 secretion, which markedly enhanced CD4+ and CD8+ T cell accumulation. Clinical validation through multiplex immunofluorescence staining on a tissue microarray of 129 glioma samples revealed a progressive loss of ZBTB7B protein expression across WHO grades II to IV, inversely correlating with tumor malignancy. These findings demonstrate ZBTB7B as a dual-function tumor suppressor that concurrently induces intrinsic apoptosis and remodels the tumor immune microenvironment in glioma toward a ‘hot’ phenotype. Therefore, we propose ZBTB7B reactivation as a novel therapeutic strategy for glioma.